Mets second baseman Robinson Cano will be suspended for 162 games - the length of a normal MLB season - after testing positive for a performance-enhancing substance, Major League Baseball announced Wednesday.

Cano tested positive for Stanozolol, according to MLB.

He will forfeit his $24 million salary for the 2021 season. He is scheduled to make $24 million in 2022 and 2023, the last two years of a 10-year, $240 million contract he signed with the Seattle Mariners before the 2014 season.

This is Cano’s second suspension for using a performance-enhancing drug. He was also suspended for 80 games in 2018, while he was a member of the Mariners.

Cano was acquired by the Mets from the Mariners before the 2019 season, along with closer Edwin Diaz, in a trade that saw the Mets send top prospects Jarred Kelenic and Justin Dunn to Seattle, among others.

He had a down season in 2019, hitting just .256 with 13 home runs and a .428 slugging percentage in 390 at-bats in 2019, but rebounded in the pandemic-shortened 2020 to hit .316 with 10 home runs and a .544 slugging percentage in 171 at-bats.

Cano began his career with the Yankees in 2005 and played in the Bronx through the 2013 season. He made five All-Star appearances as a Yankee and won a World Series title in 2009. He made three more All-Star appearances during his time in Seattle.